Additional Phase 1 Clinical Data Presented at EASL 2026
Waist Circumference Reduced by Up to 9.8 cm

Metabia, an affiliate of Dong-A ST, announced on May 28 that it presented additional Phase 1 clinical data on its GLP-1·glucagon dual-action anti-obesity drug candidate 'DA-1726' at the Annual Congress of the European Association for the Study of the Liver (EASL Congress 2026).


MetaVia company logo image. MetaVia

MetaVia company logo image. MetaVia

View original image

The presentation was held during the latest clinical poster session. Metabia released research findings under the theme "Exploration of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Non-Invasive Liver Assessments of DA-1726 in a High-Dose Phase 1 Clinical Trial."


The study was a randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) Phase 1 clinical trial conducted in healthy adults with obesity. Participants received either DA-1726 or placebo for four weeks without dose escalation, and some received an additional four-week extension at the same dose.


The results demonstrated safety and tolerability in the 48mg high-dose group. There were no serious adverse events or cases of treatment discontinuation, and gastrointestinal adverse events were mostly mild or moderate and transient. Despite glucagon receptor activation, no clinically meaningful changes were observed in cardiovascular parameters such as heart rate or QTcF.


The weight loss effect was also confirmed. In the 48mg group, the average body weight decreased by 6.1% on day 26 and by 9.1% on day 54 after administration. No plateau in weight loss was observed up to week 8. Waist circumference decreased by an average of 5.8 cm on day 26 and 9.8 cm on day 54.


Exploratory analyses based on non-invasive liver assessments also indicated the potential for improvement in indicators related to fatty liver and liver fibrosis. The controlled attenuation parameter (CAP), a marker for fatty liver, decreased in the 48mg group but increased in the placebo group. Vibration-controlled transient elastography (VCTE), which measures liver stiffness, also showed a decrease from baseline in the 48mg group and an increase in the placebo group. The FAST score also improved from baseline.


Metabia explained that, based on these results, it has confirmed the development potential of DA-1726 as a treatment for obesity-related liver diseases and MASH (metabolic dysfunction-associated steatohepatitis).


DA-1726 is an anti-obesity drug candidate in the oxyntomodulin analog class. It works by simultaneously activating the GLP-1 and glucagon receptors, thereby suppressing appetite, promoting insulin secretion, and increasing basal metabolic rate. Metabia is currently conducting Part 3 of the Phase 1 clinical trial with both 'one-step' and 'two-step' dose escalation strategies, aiming to secure data in the fourth quarter of this year.



Hyungheon Kim, CEO of Metabia, stated, "Through this EASL presentation, we have once again confirmed the differentiated therapeutic potential and competitiveness of DA-1726 for metabolic diseases. We will continue to optimize our long-term administration strategy and high-dose tolerability, and systematically evaluate the potential in obesity and MASH fields."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing